Chester Miltenberger
Chester Miltenberger M.D. is an accomplished pool and open water swimmer who holds numerous world records and has completed two English Channel swims and two Maui Channel Swims. Dr. Miltenberger has established a highly successful private practice in Lake Mary, Florida as a specialist in Internal Medicine, Addiction Treatment and Cosmetic Services.
Contents
Swimming Career
- Four Year Letterman – Florida State University Swim Team, 1960-1973
- Captain Florida State University Swim Team, 1972-1973
- “Faces in the Crowd” Sports Illustrated – National Records June 1981 and June 1987
- World Record Breaststroke 1982, 1983, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1988 and 1999
- Cover Photo, Swim Magazine, May-June 1993
- First Person over 40 age group to complete 100 Yard Breaststroke under 60 seconds
- English Channel – 1983 and 2001
- Maui Channel Swim - 1995 and 2003
Education
- Florida State University, B.S. in Biology with Minors in Chemistry and Engineering, 1973
- University of Florida, Post Baccalaureate Study, 1973 – 1974
- University of Florida, M. D. – 1981
- University Hospital/Shands, Jacksonville, Florida, Internship & Residency – Internal Medicine
- University of South Florida, Tampa, Florida, Externship – Dermatology, 1981
- University of Miami, Externship – Dermatology, 1983
Certifications
- Certified, American Board of internal Medicine, 1985
- Diplomate, American Board of Internal Medicine - 1986
Hospital Affliations
- Florida Hospital South – Orlando, Florida (Active Staff)
- Florida Hospital North – Altamonte Springs, Florida (Active Staff)
- Central Florida Regional Hospital – Sanford, Florida (Active Staff)
Professional Memberships
- Diplomate/Member American College of Physicians
- American Medical Association- 1981 to present
- American Academy of Addiction Psychiatry
- Florida Medical Society
- Florida Society of Internal medicine
- American Society of Internal medicine
- Southern Medical Association
Medical Affiliations (Past & Present)
- Central Florida Regional Hospital, Chairman, Department of Medicine – 1986
- Medical Director – DeBary Manor Nursing Home – 1988-1998
- Medical Director – Barrington Terrace Nursing Home – 1995-1997
- Medical Director – Humana – 1989-1991
- Advisory Board Speaker: Novartis Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Lilly Pharmaceuticals, Reckitt Benckiser
Military Service
- United States Army Medical Service Corp – 1974-1975, 2nd Lieutenant – Captain
- Active Reserve – June 1975-1992 - U.S. Naval Reserve
- Inactive Reserve - 1992-Present
- Commander United States Navy Medical Corps
Research Experience
Heart Disease Outcomes: Impact of Genetics and Pharmacogenetics (INVEST Sub-study) – 1998
An Open, Randomized, Parallel-Group, Multicenter Trial to Compare a Stratified Care Treatment Regimen based on Migraine Disability (MIDAS grade) versus Standard Therapy for the Acute Treatment of Migraine Headache – 2000
Randomized, Open Label, Multicenter Trial of the Safety and Effectiveness of Oral Telithromycin (Ketekâ) and Amoxicillin/Clavulanic Acid (Augmentinâ) in Outpatients with Respiratory Infections in Usual Care Settings – 2000
A Multicenter, Randomized, Open-label Comparison of the Effects of ZOMIG-ZMTÔ (zolmitriptan) and Usual Migraine Care on Work Loss, Productivity, and Patient Preference – 2001
Glycemia Optimization Treatment (GOT): To Assess the Safety of Glucose Control as measured by the Frequency of Severe Hypoglycemia Events Using Dosing Algorithms Based on Different Fasting Blood Glucose Goals with Lantus (Insulin Glargine [rDNA Origin] in Adult Individuals with Type 2 Diabetes Who Have Not Achieved the Target A1c Goal of <7% with Oral Hypoglycemia Agents: A Randomized, Open-Label, Parallel-Design Trial – 2002
Impact of Point-of-Care vs. Laboratory Testing of Hemoglobin A1c (HbA1c) and Intense vs. Standard Monitoring of Titration Algorithm Adherence on Glycemic Control in Type 2 Diabetes Subjects, Who Are Inadequately Controlled on Oral Anti-Hyperglycemic Therapy, and Starting Lantusâ (Insulin Glargine [rDNA origin] Injection): A 2X2, Randomized, Open-Label Trial – 2002
